Background: Mosaic immunogens are bioinformatically engineered human immunodeficiency virus type 1 (HIV-1) sequences designed to elicit clade-independent coverage against globally circulating HIV-1 strains. Methods: This phase 1, double-blinded, randomized, placebo-controlled trial enrolled healthy HIV-uninfected adults who received 2 doses of amodified vaccinia Ankara (MVA)-vectored HIV-1 bivalent mosaic immunogen vaccine or placeboon days 0 and 84. Two groups were enrolled: those who were HIV-1 vaccine naive (n = 15) and those who had received an HIV-1 vaccine (Ad26.ENVA.01) 4-6 years earlier (n = 10). We performed prespecified blinded cellular and humoral immunogenicity analyses at days 0, 14, 28, 84, 98, 112, 168, 270, and 365. Results: All 50 planned vaccinations were administered. Vaccination was safe and generally well tolerated. No vaccine-related serious adverse events occurred. Both cellular and humoral cross-clade immune responses were elicited after 1 or 2 vaccinations in all participants in the HIV-1 vaccine-naive group. Env-specific responses were induced after a single immunization in nearly all subjects who had previously received the prototype Ad26.ENVA.01 vaccine. Conclusions: No safety concerns were identified, and multiclade HIV-1-specific immune responses were elicited. Clinical Trials Registration: NCT02218125.
RCT Entities:
Background: Mosaic immunogens are bioinformatically engineered human immunodeficiency virus type 1 (HIV-1) sequences designed to elicit clade-independent coverage against globally circulating HIV-1 strains. Methods: This phase 1, double-blinded, randomized, placebo-controlled trial enrolled healthy HIV-uninfected adults who received 2 doses of a modified vaccinia Ankara (MVA)-vectored HIV-1 bivalent mosaic immunogen vaccine or placebo on days 0 and 84. Two groups were enrolled: those who were HIV-1 vaccine naive (n = 15) and those who had received an HIV-1 vaccine (Ad26.ENVA.01) 4-6 years earlier (n = 10). We performed prespecified blinded cellular and humoral immunogenicity analyses at days 0, 14, 28, 84, 98, 112, 168, 270, and 365. Results: All 50 planned vaccinations were administered. Vaccination was safe and generally well tolerated. No vaccine-related serious adverse events occurred. Both cellular and humoral cross-clade immune responses were elicited after 1 or 2 vaccinations in all participants in the HIV-1 vaccine-naive group. Env-specific responses were induced after a single immunization in nearly all subjects who had previously received the prototype Ad26.ENVA.01 vaccine. Conclusions: No safety concerns were identified, and multiclade HIV-1-specific immune responses were elicited. Clinical Trials Registration: NCT02218125.
Authors: Paul A Goepfert; Marnie L Elizaga; Alicia Sato; Li Qin; Massimo Cardinali; Christine M Hay; John Hural; Stephen C DeRosa; Olivier D DeFawe; Georgia D Tomaras; David C Montefiori; Yongxian Xu; Lilin Lai; Spyros A Kalams; Lindsey R Baden; Sharon E Frey; William A Blattner; Linda S Wyatt; Bernard Moss; Harriet L Robinson Journal: J Infect Dis Date: 2011-01-31 Impact factor: 5.226
Authors: Fusheng Li; Uma Malhotra; Peter B Gilbert; Natalie R Hawkins; Ann C Duerr; Juliana M McElrath; Lawrence Corey; Steven G Self Journal: Vaccine Date: 2006-06-27 Impact factor: 3.641
Authors: Michael C Keefer; Sharon E Frey; Marnie Elizaga; Barbara Metch; Stephen C De Rosa; Paulo F Barroso; Georgia Tomaras; Massimo Cardinali; Paul Goepfert; Artur Kalichman; Valérie Philippon; M Juliana McElrath; Xia Jin; Guido Ferrari; Olivier D Defawe; Gail P Mazzara; David Montefiori; Michael Pensiero; Dennis L Panicali; Lawrence Corey Journal: Vaccine Date: 2011-01-07 Impact factor: 3.641
Authors: Sampa Santra; Mark Muldoon; Sydeaka Watson; Adam Buzby; Harikrishnan Balachandran; Kevin R Carlson; Linh Mach; Wing-Pui Kong; Krisha McKee; Zhi-Yong Yang; Srinivas S Rao; John R Mascola; Gary J Nabel; Bette T Korber; Norman L Letvin Journal: Virology Date: 2012-04-21 Impact factor: 3.616
Authors: Scott M Hammer; Magdalena E Sobieszczyk; Holly Janes; Shelly T Karuna; Mark J Mulligan; Doug Grove; Beryl A Koblin; Susan P Buchbinder; Michael C Keefer; Georgia D Tomaras; Nicole Frahm; John Hural; Chuka Anude; Barney S Graham; Mary E Enama; Elizabeth Adams; Edwin DeJesus; Richard M Novak; Ian Frank; Carter Bentley; Shelly Ramirez; Rong Fu; Richard A Koup; John R Mascola; Gary J Nabel; David C Montefiori; James Kublin; M Juliana McElrath; Lawrence Corey; Peter B Gilbert Journal: N Engl J Med Date: 2013-10-07 Impact factor: 91.245
Authors: Marcella Sarzotti-Kelsoe; Robert T Bailer; Ellen Turk; Chen-li Lin; Miroslawa Bilska; Kelli M Greene; Hongmei Gao; Christopher A Todd; Daniel A Ozaki; Michael S Seaman; John R Mascola; David C Montefiori Journal: J Immunol Methods Date: 2013-12-01 Impact factor: 2.303
Authors: Morgane Rolland; Sodsai Tovanabutra; Allan C deCamp; Nicole Frahm; Peter B Gilbert; Eric Sanders-Buell; Laura Heath; Craig A Magaret; Meera Bose; Andrea Bradfield; Annemarie O'Sullivan; Jacqueline Crossler; Teresa Jones; Marty Nau; Kim Wong; Hong Zhao; Dana N Raugi; Stephanie Sorensen; Julia N Stoddard; Brandon S Maust; Wenjie Deng; John Hural; Sheri Dubey; Nelson L Michael; John Shiver; Lawrence Corey; Fusheng Li; Steve G Self; Jerome Kim; Susan Buchbinder; Danilo R Casimiro; Michael N Robertson; Ann Duerr; M Juliana McElrath; Francine E McCutchan; James I Mullins Journal: Nat Med Date: 2011-02-27 Impact factor: 53.440
Authors: Erica N Borducchi; Crystal Cabral; Kathryn E Stephenson; Jinyan Liu; Peter Abbink; David Ng'ang'a; Joseph P Nkolola; Amanda L Brinkman; Lauren Peter; Benjamin C Lee; Jessica Jimenez; David Jetton; Jade Mondesir; Shanell Mojta; Abishek Chandrashekar; Katherine Molloy; Galit Alter; Jeffrey M Gerold; Alison L Hill; Mark G Lewis; Maria G Pau; Hanneke Schuitemaker; Joseph Hesselgesser; Romas Geleziunas; Jerome H Kim; Merlin L Robb; Nelson L Michael; Dan H Barouch Journal: Nature Date: 2016-11-09 Impact factor: 49.962
Authors: Franco Pissani; Bianca Schulte; Michael A Eller; Bruce T Schultz; Silvia Ratto-Kim; Mary Marovich; Prasert Thongcharoen; Somchai Sriplienchan; Supachai Rerks-Ngarm; Punnee Pitisuttithum; Stefan Esser; Galit Alter; Merlin L Robb; Jerome H Kim; Nelson L Michael; Hendrik Streeck Journal: J Virol Date: 2018-11-12 Impact factor: 5.103
Authors: Hung V Trinh; Neelakshi Gohain; Peter T Pham; Christopher Hamlin; Hongshuo Song; Eric Sanders-Buell; Meera Bose; Leigh A Eller; Swati Jain; Gherman Uritskiy; Venigalla B Rao; Sodsai Tovanabutra; Nelson L Michael; Merlin L Robb; M Gordon Joyce; Mangala Rao Journal: Cells Date: 2019-04-19 Impact factor: 6.600
Authors: Wesley de Jong; Lorna Leal; Jozefien Buyze; Pieter Pannus; Alberto Guardo; Maria Salgado; Beatriz Mothe; Jose Molto; Sara Moron-Lopez; Cristina Gálvez; Eric Florence; Guido Vanham; Eric van Gorp; Christian Brander; Sabine Allard; Kris Thielemans; Javier Martinez-Picado; Montserrat Plana; Felipe García; Rob A Gruters Journal: Vaccines (Basel) Date: 2019-12-06
Authors: Kai Qin; Sushma Boppana; Anju Bansal; Paul Goepfert; Jonathan M Carlson; Andrew Fiore-Gartland; Jacob Files; Jie Zeng; Jeffrey Edberg; Robbie B Mailliard; Christina Ochsenbauer Journal: J Virol Date: 2021-07-26 Impact factor: 5.103
Authors: Adrien Leite Pereira; Quentin Jouhault; Ernesto Marcos Lopez; Antonio Cosma; Olivier Lambotte; Roger Le Grand; Michael H Lehmann; Nicolas Tchitchek Journal: Front Immunol Date: 2020-09-08 Impact factor: 7.561
Authors: Lindsey R Baden; Daniel J Stieh; Michal Sarnecki; Stephen R Walsh; Georgia D Tomaras; James G Kublin; M Juliana McElrath; Galit Alter; Guido Ferrari; David Montefiori; Philipp Mann; Steven Nijs; Katleen Callewaert; Paul Goepfert; Srilatha Edupuganti; Etienne Karita; Johannes P Langedijk; Frank Wegmann; Lawrence Corey; Maria G Pau; Dan H Barouch; Hanneke Schuitemaker; Frank Tomaka Journal: Lancet HIV Date: 2020-10 Impact factor: 12.767
Authors: Ed McGowan; Rachel Rosenthal; Andrew Fiore-Gartland; Gladys Macharia; Sheila Balinda; Anne Kapaata; Gisele Umviligihozo; Erick Muok; Jama Dalel; Claire L Streatfield; Helen Coutinho; Dario Dilernia; Daniela C Monaco; David Morrison; Ling Yue; Eric Hunter; Morten Nielsen; Jill Gilmour; Jonathan Hare Journal: Front Immunol Date: 2021-02-18 Impact factor: 7.561